

KOBO BIOTECH LIMITED

Corp. Office: Unit 505, Hyde Park, Saki Vihar Road,
Opp. Ansa Industrial Estate, Andheri (E), Mumbai - 400 072
Tel.: +91-22 4287 1210 • Fax: +91-22-4287 1285
E-mail: info@kobobiotech.com • Website: www.kobobiotech.com
(CIN : L24110TG1993PLC16112)

11th August, 2023

Corporate Service Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001
Scrip: Equity 531541

Dear Sir/ Madam,

Scrip Name: **Kobo Biotech Limited**, Scrip Code: **531541**

Sub: OUTCOME OF THE BOARD MEETING: Unaudited Financial results for the Quarter ended 30th June, 2023.

This is to inform you that the Board of Directors of Kobo Biotech Limited at their meeting held today i.e. on Friday, 11th August, 2023 inter alia approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2023 alongwith the Limited review report of statutory auditor thereon.

Please find enclosed a copy of the unaudited Financials along with Limited Review report from the Statutory Auditors.

Further, we wish to inform you that Board of Directors of the Company based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the Members of the Company, has approved the proposals for reappointment of Mrs. Urja Vijaykumar Shah, (DIN: 06672899), as an Independent Director of the Company, for a second term of Five years from 27th December, 2023 to 26th December, 2028.

The Company proposes to seek Members' approval for the above proposal at the forthcoming Annual General Meeting of the Company.

Additional details pursuant to Regulation 30 and other relevant provisions of the SEBI Listing Regulations is enclosed as Annexure-1.

The above is pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, for your information and record.

The above-referred meeting was commenced at 3:00 p.m. and concluded at 4:10 p.m.

Thank you,

For Kobo Biotech Limited

Jignesh Patel
Company Secretary

KOBO BIOTECH LIMITED

Corp. Office: Unit 505, Hyde Park, Saki Vihar Road,
Opp. Ansa Industrial Estate, Andheri (E), Mumbai - 400 072
Tel.: +91-22 4287 1210 • Fax: +91-22-4287 1285
E-mail: info@kobobiotech.com • Website: www.kobobiotech.com
(CIN : L24110TG1993PLC16112)

Annexure - 1 Additional Details as required under Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reappointment of Mrs. Urja Vijaykumar Shah as an Independent Director of the Company for a second term.

| SN | Particulars | Remarks |
|----------|--|---|
| | | Mrs. Urja Vijaykumar Shah |
| 1 | Reason for change viz., appointment, resignation, removal, death or otherwise | Reappointment of Mrs. Urja Vijaykumar Shah as an Independent Director of the Company for a second term. |
| 2 | Date of appointment/ cessation (as applicable) & terms of appointment | Five Years: 27 th December, 2023 to 26 th December, 2028 |
| 3 | Brief Profile | Ms. Urja is a qualified Company Secretary, Graduate in Law and a Commerce Graduate. She has varied professional experience and interests ranging from Audit, Consultancy, Advisory, Farming and Astronomy. Ms. Urja has over 10 years of experience in finance and regulatory field, FEMA, RERA, FSSAI. |
| 4 | Disclosure of relationship between directors | Ms. Urja is not related to any of the Directors of the Company. |
| 5 | Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively. | Ms. Urja is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority. |



A N Shah & Associates
Chartered Accountants

C/303, Anand Nagar,
Forjett Street,
Opp. Bhatia Hospital,
Mumbai – 400 036.
Tel: +91 22 4976 9085

Limited Review Report of Un-audited Financial Results of Kobo Biotech Limited

Independent Auditor's Review Report on Quarter ended Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of
Kobo Biotech Limited
Mumbai.

Report on the Statement of Unaudited Financial Results

We have reviewed the accompanying statement of unaudited financial results of **Kobo Biotech Limited** ("the Company") for the quarter ended 30th June 2023, which are included in the accompanying Statement of Unaudited Financial Results for the quarter ended 30th June 2023, including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flows for the half-year ended on that date ("the Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations, 2015"), including relevant circulars issued by the SEBI from time to time. We have initialed the Statement for identification Purposes only. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

A N Shah & Associates
Chartered Accountants

C/303, 3rd Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158
Email id: ca.akashshah3033@gmail.com



A N Shah & Associates
Chartered Accountants

C/303, Anand Nagar,
Forjett Street,
Opp. Bhatia Hospital,
Mumbai – 400 036.
Tel: +91 22 4976 9085

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; and
- (ii) Give a true and fair view in conformity with the aforesaid accounting standards and other accounting principles generally accepted in India of the net Loss and other financial information of the company for the quarter ended 30th June, 2023.

For,
A N Shah & Associates,
Chartered Accountants

Akash Shah
Proprietor



Date: 11 August, 2023
Place: Mumbai
UDIN: 23191340BGSPZN4590

A N Shah & Associates
Chartered Accountants

C/303, 3rd Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158
Email id: ca.akashshah3033@gmail.com

KOBO BIOTECH LIMITED

CIN: L24110TG1993PLC016112

Regd. Office : 505, Plot No.193 & 193/1, Chandi Nilayam, Samatha Nagar, Bhagyanagar 3rd Phase, Kukatpally, Hyderabad - 500 085

Corp. Office : Unit 505, Hyde Park, Saki Vihar Road, Opp. Ansa Industrial Estate, Andheri (E), Mumbai - 400 072

Statement of Audited Financial Results for the quarter ended 30th June, 2023

(Amount in INR Lakhs)

| Sr. No. | PARTICULARS | Quarter Ended | | | Year Ended |
|---------|---|---------------|------------|-------------|-------------|
| | | 30.06.2023 | 31.03.2023 | 30.06.2022 | 31.03.2023 |
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| I | Income from operations | 0.00 | 0.00 | 0.00 | 0.00 |
| II | Other Income | 1.52 | 0.00 | 1.52 | 1.52 |
| III | Total Income (I+II) | 1.52 | 0.00 | 1.52 | 1.52 |
| IV | Expenditure | | | | |
| | (a) Cost of raw material consumed | 0.00 | 0.00 | 0.00 | 0.00 |
| | (b) Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 |
| | (c) Employee benefits expense | 5.52 | 6.02 | 5.45 | 23.01 |
| | (d) Finance Cost | 0.00 | 0.02 | 0.00 | 0.02 |
| | (e) Depreciation and Amortisation expenses | 101.27 | 100.30 | 115.12 | 407.19 |
| | (f) Exchange(Gain)/Loss | 0.00 | 0.00 | 0.00 | 0.00 |
| | (g) Other Expenses | 17.30 | 73.00 | 27.64 | 126.64 |
| | Total Expenses | 124.09 | 179.34 | 148.21 | 556.86 |
| V | Profit (Loss) before Exceptional Items and Tax (III-IV) | (122.57) | (179.34) | (146.69) | (555.34) |
| VI | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 |
| VII | Profit (Loss) before Tax (V-VI) | (122.57) | (179.34) | (146.69) | (555.34) |
| VIII | Tax expenses | | | | |
| | (a) Current Tax | 0.00 | 0.00 | 0.00 | 0.00 |
| | (b) Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 |
| IX | Net Profit (Loss) after tax (VII-VIII) | (122.57) | (179.34) | (146.69) | (555.34) |
| X | Other Comprehensive Income | | | | |
| | (i) Items that will not be reclassified to Profit or Loss | 0.00 | 0.00 | 0.00 | 0.00 |
| XI | Total Comprehensive Income for the period (IX+X) | (122.57) | (179.34) | (146.69) | (555.34) |
| XII | Paid-up equity share capital | | | | 2,382.50 |
| XIII | Other Equity | | | | (15,180.65) |
| XIV | Earnings Per Share (Basic and Diluted) (in Rs) | (0.51) | (0.75) | (0.62) | (2.33) |

Notes:

| | |
|---|---|
| 1 | The above audited standalone financial results, prepared in accordance with the Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 and guidelines issued by the Securities and Exchange Board of India, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th August, 2023. |
| 2 | The Company operates only in one Business Segment i.e. manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs. |
| 3 | Due to no operational activities at the Company for the past 7 years, the Employee benefit expenses for the quarter is considered only for the Employees who are reporting to work. Similarly, the interest cost for the quarter is not being provided for, as majority of the loans have been assigned to a leading ARC. |
| 4 | The number of investor complaints at the beginning and pending at the end of the Quarter were Nil. |
| 5 | Figures for the quarter ended 31st March are the balancing figures between the audited figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year, which were subjected to limited review |
| 6 | Figures of the previous periods have been regrouped / rearranged wherever considered necessary. |

By order of the Board
For KOCO BIOTECH LIMITED



Ajit Kamath
Chairman

Mumbai
11-08-2023